China Medical University, China
Clinical trials sponsored by China Medical University, China, explained in plain language.
-
New drug combo aims to keep advanced lung cancer in check
Disease control Not yet recruitingThis study tests a combination of drugs (liposomal irinotecan, platinum, an immune checkpoint inhibitor, and anlotinib) as maintenance therapy for people with extensive small cell lung cancer after initial treatment. The goal is to see if this mix can delay cancer growth and impr…
Phase: PHASE2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated May 02, 2026 00:14 UTC
-
Triple attack: virus therapy plus two drugs targets liver tumors
Disease control Not yet recruitingThis early-stage study tests a new treatment for colorectal cancer that has spread to the liver. The treatment combines a modified virus (BioTTT001) with two drugs (toripalimab and regorafenib) to attack the cancer. The main goals are to check safety and find the best dose. About…
Phase: PHASE1 • Sponsor: China Medical University, China • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug combo offers hope for tough lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 adults with extensive-stage small cell lung cancer that has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth. Participant…
Phase: PHASE2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC